Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
May 12, 2026
JBS N.V. (JBS): What to Expect from Q1 2026 Earnings

JBS N.V. (JBS): What to Expect from Q1 2026 Earnings

Key Takeaways

  • Analysts expect Q1 2026 revenue of approximately $21.7 billion, reflecting modest growth amid protein demand.
  • Consensus EPS estimate stands at $0.24, building on Q4 2025's $0.39 reported figure.
  • Investors watching adjusted EBITDA margins, with focus on beef, pork, and poultry segments.
  • Company guidance emphasizes capex at $2.4 billion for 2026, targeting leverage below 2.5x.
  • Historical beats on revenue in recent quarters, though EPS mixed.
  • Stock has shown resilience, up amid analyst upgrades ahead of report.

Understanding JBS Earnings and Their Importance

As the world's largest protein producer, JBS N.V. (JBS) manages a diversified portfolio that includes beef, pork, poultry, and processed foods across North America, Brazil, Australia, and Europe. After delivering record full-year 2025 revenue of $86 billion and net income of $2 billion, the upcoming Q1 2026 earnings report will provide insight into whether that momentum continues, particularly with tight U.S. cattle supplies and shifting global demand. From my perspective, this report is crucial for investors because it sheds light on operational efficiency, segment performance, and capital allocation decisions in a challenging commodity market. With shares trading near recent highs following the NYSE listing, the results could indicate if JBS can sustain its advantage across multiple proteins amid inflation and supply chain issues, which would also have implications for peers like Pilgrim's Pride.

Breaking Down the Earnings Expectations

Analysts are forecasting consensus revenue of $21.68 billion for Q1 2026 (January-March), a slight increase from prior periods, supported by volume growth in poultry and prepared foods that should offset headwinds in beef. The EPS consensus comes in at $0.24, with estimates ranging from $0.20 to $0.32—this follows Q4 2025's reported $0.39 against an expected $0.41. Key figures to watch include adjusted EBITDA, with margins projected around 7-8% in line with full-year trends, and leverage moving toward 2.5x or lower.

Looking back, the company has consistently beaten revenue expectations: Q4 2025 came in at $23.06 billion versus $22.6 billion anticipated (+15% YoY), and Q3 hit $22.6 billion (also a beat). EPS results have been more varied, with Q4 slightly missing the mark but full-year EPS rising 15% to $1.89. Stock reactions have been muted post-Q4 despite the revenue strength. I expect guidance to cover 2026 capex of $2.4 billion (split between expansion and maintenance) along with working capital requirements.

Market Sentiment Ahead of the Report

Investor sentiment heading into Q1 earnings feels cautiously optimistic. Recent analyst upgrades, such as Goldman Sachs' 'Buy' rating with a $48 price target, have pushed shares to 7-month highs. The overall consensus remains a Strong Buy, supported by the strong 2025 performance. That said, risks persist from tight U.S. beef supplies and elevated grain costs. Historically, beats have led to 5-10% upside, while misses could add pressure in this volatile environment. One thing that stands out to me is how resilient the stock has been amid these upgrades.

AI Screener: A Tool I Rely On for Analysis

In reviewing JBS, I also checked this using Tickeron’s AI Screener, which helps me filter stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It scans thousands of instruments with customizable filters like industry, market cap, technical indicators, price patterns, and performance metrics, making it easier to spot trade ideas, trending stocks, breakout candidates, and opportunities that might otherwise take hours to uncover manually. I find it particularly useful for comparing companies like JBS against sector peers efficiently.

Looking Ahead: Guidance and Factors to Track

Once earnings are out, attention will turn to reaffirmation of 2026 guidance. Management aims for EBITDA cash flow breakeven at $5.7 billion, factoring in $2.4 billion in capex and stable working capital—this should support free cash flow after 2025's $400 million generation.

Segment performance deserves close monitoring: Beef in North America continues to face cattle supply constraints into 2026, though exports from Australia and Brazil provide some balance. Upside potential lies in poultry (Pilgrim's Pride, Seara) and U.S. pork expansions, including new Iowa plants ramping up by 2027 to add $500-750 million in revenue at double-digit margins. Prepared foods have shown resilience with growth exceeding 25% in recent quarters.

Broader macro influences include commodity prices for grains and livestock, currency fluctuations (BRL/USD), and demand trends in China and the EU following reopenings. Leverage stood at 2.39x at Q4's end, providing room for buybacks and dividends ($1/share ex-May 18), with $7.4 billion in liquidity enabling opportunistic M&A. I'm watching Q2 trends closely as they will shape the full-year path toward revenue exceeding $88 billion.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: JBS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


JBS in upward trend: price rose above 50-day moving average on July 24, 2026

JBS moved above its 50-day moving average on July 24, 2026 date and that indicates a change from a downward trend to an upward trend. In of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 52 cases where JBS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 10-day moving average for JBS crossed bullishly above the 50-day moving average on July 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JBS advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 234 cases where JBS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for JBS moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JBS as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for JBS turned negative on August 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JBS broke above its upper Bollinger Band on July 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.528) is normal, around the industry mean (8.481). P/E Ratio (12.916) is within average values for comparable stocks, (36.558). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.944). Dividend Yield (0.072) settles around the average of (0.055) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (5.907).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. JBS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

Notable companies

The most notable companies in this group are Kraft Heinz Company (The) (NASDAQ:KHC), General Mills (NYSE:GIS), The Campbell's Company (NASDAQ:CPB), Beyond Meat Inc. (NASDAQ:BYND).

Industry description

Companies in this industry usually make a diverse range of agricultural and/or processed food. Some prominent names in this segment are Mondelez International, which makes chocolates, biscuits, cookies etc. The Kraft Heinz Company specializes in ketchups, sauces, fruit drink pouches and many more. General Mills, Inc. sells flour and cereal. Kellogg is famous for its snacks and breakfast cereal. And so on down the line. As more and more consumers are looking for healthier options in food in recent years, several legacy food companies have responded by revamping brands to include organic and no-added-sugar versions, and/or acquiring healthy food firms, and even streamlining operations.

Market Cap

The average market capitalization across the Food: Major Diversified Industry is 3.33B. The market cap for tickers in the group ranges from 68.52K to 255.67B. NSRGY holds the highest valuation in this group at 255.67B. The lowest valued company is THRC at 68.52K.

High and low price notable news

The average weekly price growth across all stocks in the Food: Major Diversified Industry was 0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was -8%. BRLS experienced the highest price growth at 114%, while BRCC experienced the biggest fall at -90%.

Volume

The average weekly volume growth across all stocks in the Food: Major Diversified Industry was 14%. For the same stocks of the Industry, the average monthly volume growth was -8% and the average quarterly volume growth was -28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 61
Price Growth Rating: 59
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: -16 (-100 ... +100)
View a ticker or compare two or three
JBS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry FoodMajorDiversified

Profile
Details
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.
JBS N.V. (JBS): What to Expect from Q1 2026 Earnings